{"id":"isolated-pelvis-perfusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Limb toxicity / lower extremity complications"},{"rate":null,"effect":"Hematologic toxicity"},{"rate":null,"effect":"Renal toxicity"},{"rate":null,"effect":"Vascular complications"}]},"_chembl":{"chemblId":"CHEMBL30792","moleculeType":"Small molecule","molecularWeight":"483.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a regional chemotherapy delivery technique that isolates the blood supply to the pelvis and perfuses chemotherapeutic agents directly into the isolated vascular bed. By limiting drug exposure to the target region, the approach allows for higher local drug concentrations while reducing systemic toxicity. It is typically used for advanced pelvic malignancies that are unresectable or at high risk of recurrence.","oneSentence":"Isolated pelvic perfusion delivers high-dose chemotherapy directly to pelvic tumors while minimizing systemic exposure through regional vascular isolation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:19.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced pelvic malignancies (sarcoma, gynecologic cancers, colorectal cancer)"},{"name":"Locally advanced or unresectable pelvic tumors"}]},"trialDetails":[{"nctId":"NCT00949039","phase":"PHASE3","title":"Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2009-02","conditions":"Gynaecologic or Digestive Pelvic Cancer","enrollment":101},{"nctId":"NCT00181025","phase":"PHASE2","title":"Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle","status":"UNKNOWN","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2004-05","conditions":"Sarcoma of Pelvis","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Isolated pelvis perfusion","genericName":"Isolated pelvis perfusion","companyName":"Gustave Roussy, Cancer Campus, Grand Paris","companyId":"gustave-roussy-cancer-campus-grand-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isolated pelvic perfusion delivers high-dose chemotherapy directly to pelvic tumors while minimizing systemic exposure through regional vascular isolation. Used for Advanced pelvic malignancies (sarcoma, gynecologic cancers, colorectal cancer), Locally advanced or unresectable pelvic tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}